Brief: Abbisko Cayman Says FY Loss Attributable RMB495.6 Mln
15/03/2023 11:33
March 15 (Reuters) - Abbisko Cayman Ltd 2256.HK :
* FY LOSS ATTRIBUTABLE RMB495.6 MILLION VERSUS LOSS RMB1.81
BILLION
* DO NOT EXPECT PANDEMIC TO HAVE ANY MATERIAL IMPACT ON
OVERALL
CLINICAL DEVELOPMENT PLANS IN LONG TERM
Source text for Eikon: ID:nHKS4xRWt0
Further company coverage: 2256.HK
Recent news on Abbisko Medicine
See all newsChina's Abbisko jumps on positive clinical trial results for achondroplasia drug
Brief: Abbisko Cayman Says Unit Completes First Patient Dosing In Phase I Trial Of ABSK211
Brief: Abbisko Cayman Gets IND Clearance From FDA For Oral Small Molecule Pan-Kras Inhibitor ABSK211
HK-listed Abbisko hits 7-week peak on AstraZeneca tie-up
Brief: Abbisko Therapeutics And Astrazeneca Enter A Strategic Collaboration